Cellectis Therapeutics, a Cellectis subsidiary specializing in the development of therapeutic applications in genome engineering, has named Dr. Andrew M. Scharenberg chief scientific officer.

Dr. Scharenberg is an attending physician in immunology at Seattle Children's Hospital, and a professor of pediatrics and immunology at the University of Washington. He is a principal investigator and co-director of the Northwest Genome Engineering Consortium and also a co-founder and member of the board of directors of Pregenen.